首站-论文投稿智能助手
典型文献
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
文献摘要:
It is an urgent demand worldwide to control the coronavirus disease 2019(COVID-19)pandemic caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)virus.The 3-chymotrypsin-like protease(3CLpro)and papain-like protease(PLpro)are key targets to discover SARS-CoV-2 inhibitors.After screening 12 Chinese herbal medicines and 125 compounds from licorice,we found that a popular natural product schaftoside inhibited 3CLpro and PLpro with IC50 values of 1.73 士 0.22 and 3.91 士 0.19 μmol/L,respectively,and inhibited SARS-CoV-2 virus in Vero E6 cells with EC50 of 11.83±3.23 μmol/L.Hydrogen-deuterium exchange mass spectrometry analysis,quantum mechanics/molecular mechanics calculations,together with site-directed mutagenesis indicated the anti-viral activities of schaftoside were related with non-covalent interactions with H41,G143 and R188 of 3CLpro,and K157,E167 and A246 of PLpro.Moreover,proteomics analysis and cytokine assay revealed that schaftoside also regulated immune response and inflammation of the host cells.The anti-inflammatory activities of schaftoside were confirmed on lipopolysaccharide-induced acute lung injury mice.Schaftoside showed good safety and pharmacokinetic property,and could be a promising drug candidate for the prevention and treatment of COVID-19.
文献关键词:
作者姓名:
Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye
作者机构:
State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;CAS Key Laboratory of Special Pathogens and Biosafety,Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Faculty of Science and Technology,University of Silesia,Katowice 40-007,Poland;Department of Physical and Quantum Chemistry,Faculty of Chemistry,Wroclaw University of Science and Technology,Wroclaw 50-370,Poland
引用格式:
[1]Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye-.Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19)[J].药学学报(英文版),2022(11):4154-4164
A类:
Schaftoside,schaftoside,H41,G143,R188,K157,E167,A246
B类:
inhibits,3CLpro,PLpro,SARS,CoV,regulates,immune,response,inflammation,host,cells,treatment,It,urgent,demand,worldwide,control,coronavirus,disease,pandemic,caused,by,severe,acute,respiratory,syndrome,chymotrypsin,like,protease,papain,are,key,targets,discover,inhibitors,After,screening,Chinese,herbal,medicines,compounds,from,licorice,found,that,popular,natural,product,inhibited,IC50,values,respectively,Vero,E6,EC50,Hydrogen,deuterium,exchange,mass,spectrometry,analysis,quantum,mechanics,molecular,calculations,together,site,directed,mutagenesis,indicated,anti,viral,activities,were,related,covalent,interactions,Moreover,proteomics,cytokine,assay,revealed,also,regulated,inflammatory,confirmed,lipopolysaccharide,induced,lung,injury,mice,showed,good,safety,pharmacokinetic,property,could,be,promising,drug,candidate,prevention
AB值:
0.551935
相似文献
Common mtDNA variations at C5178a and A249d/T6392C/G10310A decrease the risk of severe COVID?19 in a Han Chinese population from Central China
Yi Wu;Xian‑Hui Wang;Xi‑Hua Li;Li‑Yuan Song;Shi‑Long Yu;Zhi‑Cheng Fang;Yu‑Quan Liu;Le‑Yong Yuan;Chun‑Yan Peng;Shen‑Yi Zhang;Wang Cheng;Hong‑Chao Ma;Li‑Feng Wang;Jun‑Ming Tang;Yun‑Fu Wang;Fu‑Yun Ji-Department of Medical Biology,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Biomedical Research,Hubei University of Medicine,Shiyan 442000,Hubei,China;Institute of Human Respiratory Disease,Xinqiao Hospital,The Army Medical University(Third Military Medical University),400037 Chongqing,China;Department of Emergency Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Geriatric Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Immunology,School of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Laboratory Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China;Hubei Key Laboratory of Embryonic Stem Cell Research,School of Basic Medical Science,Hubei University of Medicine,Shiyan 442000,Hubei,China;Department of Neurology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,Hubei,China
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid,prolonged,and broad protection against SARS-CoV-2
Junyu Chen;Pui Wang;Lunzhi Yuan;Liang Zhang;Limin Zhang;Hui Zhao;Congjie Chen;Xijing Wang;Jinle Han;Yaode Chen;Jizong Jia;Zhen Lu;Junping Hong;Zicen Lu;Qian Wang;Rirong Chen;Ruoyao Qi;Jian Ma;Min Zhou;Huan Yu;Chunlan Zhuang;Xiaohui Liu;Qiangyuan Han;Guosong Wang;Yingying Su;Quan Yuan;Tong Cheng;Ting Wu;Xiangzhong Ye;Tianying Zhang;Changgui Li;Jun Zhang;Huachen Zhu;Yixin Chen;Honglin Chen;Ningshao Xia-State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Life Sciences,School of Public Health,Xiamen University,Xiamen 361102,China;State Key Laboratory of Emerging Infectious Diseases,School of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong 999077,China;National Institute for Food and Drug Control,Beijing 102629,China;Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.,Beijing 102206,China;Guangdong-Hong Kong Joint Laboratory of Emerging Infectious Diseases/Joint Laboratory for International Collaboration in Virology and Emerging Infectious Diseases,Joint Institute of Virology(STU/HKU),Shantou University,Shantou 515063,China;EKIH Pathogen Research Institute,Shenzhen 518067,China
Parthenolide reveals an allosteric mode to inhibit the delSGylation activity of SARS-CoV-2 papain-like protease
Zhihui Zou;Huizhuang Shan;Demeng Sun;Li Xia;Yulong Shi;Jiahui Wan;Aiwu Zhou;Yunzhao Wu;Hanzhang Xu;Hu Lei;Zhijian Xu;Yingli Wu-Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Chinese Academy of Medical Sciences Research Unit 2019RU043,Shanghai Jiao Tong University School of Medicine(SJTU-SM),Shanghai 200025,China;Laboratory Medicine,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,Guangdong 510000,China;Tsinghua-Peking Center for Life Sciences,Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology(Ministry of Education),Beijing Advanced Innovation Center for Structural Biology,Department of Chemistry,Tsinghua University,Beijing 100084,China;CAS Key Laboratory of Receptor Research,Drug Discovery and Design Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2
Ya-li Zhang;Wen-xin Zhang;Jue-qian Yan;Ye-lin Tang;Wen-jing Jia;Zheng-wei Xu;Ming-jiang Xu;Nipon Chattipakorn;Yi Wang;Jian-peng Feng;Zhi-guo Liu;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Yantai University,Yantai 264005,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Zhuji Biomedicine Institute,School of Pharmaceutical Sciences,Wenzhou Medical University,Zhuji 311800,China;Cardiac Electrophysiology Research and Training Center,Faculty of Medicine,Chiang Mai University,Chiang Mai 50200,Thailand;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
Yi Wang;Sui Fang;Yan Wu;Xi Cheng;Lei-ke Zhang;Xu-rui Shen;Shuang-qu Li;Jian-rong Xu;Wei-juan Shang;Zhao-bing Gao;Bing-qing Xia-CAS Key Laboratory of Receptor Research,Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Pharmacology and Chemical Biology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Zhongshan Institute of Drug Discovery,Institution for Drug Discovery Innovation,Chinese Academy of Science,Zhongshan 528400,China
Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
Lin Wang;Yan Wu;Sheng Yao;Huan Ge;Ya Zhu;Kun Chen;Wen-zhang Chen;Yi Zhang;Wei Zhu;Hong-yang Wang;Yu Guo;Pei-xiang Ma;Peng-xuan Ren;Xiang-lei Zhang;Hui-qiong Li;Mohammad A.Ali;Wen-qing Xu;Hua-liang Jiang;Lei-ke Zhang;Li-li Zhu;Yang Ye;Wei-juan Shang;Fang Bai-Shanghai Institute for Advanced Immunochemical Studies,ShanghaiTech University,Shanghai 201210,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430064,China;Department of Natural Products Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;State Key Laboratory of Bioreactor Engineering,Shanghai Key Laboratory of New Drug Design,School of Pharmacy,East China University of Science and Technology,Shanghai 200237,China;CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology,Nankai University,Tianjin 300071,China;Department of Botany and Microbiology,College of Science,King Saud University,Riyadh,Saudi Arabia
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。